804, 322 - 11 AVENUE SW, CALGARY, A0
To Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
Aligns with FDA on Planned Pivotal Anal Cancer Study
Oncolytics Biotech Inc. Enters $75 Million Open Market Sale Agreement
Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
News, Articles of Incorporation, Bylaws
To Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
Launches Randomized Colorectal Cancer Study
Q1
FY 2025
Annual and Transition Report of Foreign Private Issuers
Administrative Withdrawal
No filings found
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to a Registration Statement for Securities of Certain Canadian Issuers